Showing results (181-190 of 205) with videos related to

Sort By:
Pageof 21
Advanced Healthcare Materials|June 9, 2025
Reinforced Polymer-Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of TrastuzumabGiovanni Bovone, Stéphane Bernhard, Guillaume Jacquot, et al.
JAMA Oncology|September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical TrialGeorge W Sledge, Masakazu Toi, Patrick Neven, et al.
American Journal of Physiology. Cell Physiology|April 16, 2026
NF-κB signaling drives rapid skeletal muscle atrophy in patients with breast cancer: The cost of fighting cancer with chemotherapyJoris Mallard, Léa Debrut, Elyse Hucteau, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|January 2, 2021
Feasibility of health-related quality of life (HRQoL) assessment for cancer patients using electronic patient-reported outcome (ePRO) in daily clinical practiceGuillaume Mouillet, Antoine Falcoz, Joëlle Fritzsch, et al.
Cancers|March 14, 2026
Germline BRCA1/2 Mutations in a Large Clinic-Based Cohort of Patients with Metastatic Breast Cancer in FranceGuillaume Meynard, Victor Pereira, Sophie Paget-Bailly, et al.
The Lancet. Oncology|June 15, 2013
6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trialXavier Pivot, Gilles Romieu, Marc Debled, et al.
European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohortXavier Pivot, Pierre Fumoleau, Jean-Yves Pierga, et al.
JAMA Oncology|March 3, 2022
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical TrialXavier Pivot, M A Georgievich, Volodymyr Shamrai, et al.
JAMA Network Open|April 6, 2023
Cardiac Safety and Efficacy of SB3 Trastuzumab Biosimilar for ERBB2-Positive Early Breast Cancer: Secondary Analysis of a Randomized Clinical TrialXavier Pivot, Javier Cortés, Diana Lüftner, et al.
The New England Journal of Medicine|December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast CancerDennis J Slamon, Patrick Neven, Stephen Chia, et al.
Pageof 21